Emergent BioSolutions to buy Adapt Pharma in $735m deal
Specialty biopharmaceutical firm Emergent BioSolutions has signed an agreement to acquire Adapt Pharma in a deal valued at around $735m.
Specialty biopharmaceutical firm Emergent BioSolutions has signed an agreement to acquire Adapt Pharma in a deal valued at around $735m.
Drugmaker Lupin has launched Drospirenone, Ethinyl Estradiol, Levomefolate Calcium tablets and Levomefolate Calcium tablets for preventing pregnancy in the US.
Camber Pharmaceuticals is voluntarily recalling all unexpired lots of Valsartan tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level, as a precautionary measure.
Perrigo, a global healthcare company, said that its board of directors approved a plan to separate its Prescription Pharmaceuticals (Rx) business following a previously announced strategic portfolio review.
Abzena said that it has completed the GMP drug substance manufacture of an ABZENA Inside product that was originally humanized using the company’s Composite Human Antibody platform.
Sun Pharmaceutical Industries has launched Kapspargo Sprinkle (metoprolol succinate) extended-release capsules in the US, for the treatment of hypertension (to lower blood pressure), angina pectoris (chest pain), and heart failure.
LEO Pharma, a Danish firm focused on developing drugs for dermatologic and thrombotic patients, has agreed to acquire the global prescription dermatology business of Bayer for an undisclosed price.
Biopharmaceutical firm Amgen has broken ground on its next-generation biomanufacturing facility in Rhode Island, US.
Pfizer has unveiled plans to invest $465m for the development of a new sterile injectable pharmaceutical production facility in Michigan, US.
UK-based life sciences group Abzena has signed GMP manufacturing and bioconjugation agreements with Australia-based Telix Pharmaceuticals.